UP601, a standardized botanical composition composed of Morus alba, Yerba mate and Magnolia officinalis for weight loss

Table 1 Liver function and lipid profiling

Group	Dose (mg/kg)	ALT (U/L)	AST (U/L)	Glucose (mg/dL)	T-chol (mg/dL)	TG (mg/dL)	LDL-C (mg/dL)	HDL-C (mg/dL)
NC	0	21.6 ± 1.7	45.3 ± 13.8	206.4 ± 46.6*	101.1 ± 17.4‡	14.1 ± 3.4†	2.8 ± 0.8‡	57.6 ± 10.4*
HFF	0	36.2 ± 21.3	58.2 ± 10.0	280.6 ± 54.6	169.4 ± 17.2	32.7 ± 11.3	8.9 ± 2.4	69.5 ± 3.4
ORI	40	17.0 ± 2.2*	45.8 ± 4.2*	238.6 ± 69.0	139.1 ± 18.0†	51.3 ± 27.1	5.0 ± 1.2†	68.6 ± 6.2
UP601	300	19.5 ± 4.8	47.7 ± 4.2*	271.3 ± 35.4	153.9 ± 9.5	18.0 ± 9.4*	5.8 ± 0.5†	65.2 ± 3.7*
UP601	450	19.8 ± 12.2	53.1 ± 19.6	219.9 ± 35.1*	140.7 ± 16.5†	14.7 ± 6.1†	5.6 ± 0.9†	65.1 ± 4.1
UP601	600	16.5 ± 7.5*	48.7 ± 19.1	186.1 ± 47.1†	118.9 ± 21.0‡	11.9 ± 4.8†	5.2 ± 1.2†	57.7 ± 10.5*

HFF-induced obese C57BL/6J mice were treated with UP601 at oral doses of 300, 450 and 600 mg/kg for 7-weeks. Orlistat (ORI) at 40 mg/kg was used as a reference compound. Serum samples were collected at necropsy. ALT alanine aminotransferase, AST aspartate aminotransferase, T-chol total cholesterol, TG triglycerides, LDL C low-density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol. NC Normal control + vehicle, HFF HFF + Vehicle, ORI HFF + orlistat, UP601 HFF + indicated concentrations of UP601. *P ≤ 0.05 compared to HFF group; †P ≤ 0.001 compared to HFF group; ‡P ≤ 0.0001 compared to HFF group

ISSN: 2662-7671